PRESS RELEASE published on 08/26/2026 at 18:30, 2 months 10 days ago Heidelberg Pharma AG and Huadong Medicine Receive NMPA Approval for Clinical Trial of HDP-101 Combination Therapy in China Heidelberg Pharma AG and Huadong Medicine receive NMPA approval for Phase Ib/II clinical trial of HDP-101 combination therapy in China. Evaluation of BCMA-targeting ADC in patients with multiple myeloma NMPA Approval Clinical Trial Heidelberg Pharma Huadong Medicine ADC Therapy
BRIEF published on 07/15/2026 at 07:16, 3 months 22 days ago Heidelberg Pharma annonce des résultats positifs pour le premier semestre 2026 Rapport Financier Heidelberg Pharma AG Pamlectabart Tismanitin Premier Semestre 2026 Essais Cliniques De Phase IIa
BRIEF published on 07/15/2026 at 07:16, 3 months 22 days ago Heidelberg Pharma Reports Positive First Half-Year of 2026 Financial Report Heidelberg Pharma AG Pamlectabart Tismanitin First Half-Year 2026 Phase IIa Clinical Trials
PRESS RELEASE published on 07/15/2026 at 07:11, 3 months 22 days ago Heidelberg Pharma Reports on First Half-Year 2026 and the Positive Course of Business Heidelberg Pharma AG reports positive first half-year 2026 results, reaching milestones in clinical development and financial stability Clinical Development Milestones Financial Stability Heidelberg Pharma AG First Half-Year
BRIEF published on 06/23/2026 at 15:44, 4 months 12 days ago Heidelberg Pharma's Annual General Meeting 2026 Overview Annual General Meeting Shareholder Approval Supervisory Board Heidelberg Pharma Antibody Drug Conjugates
BRIEF published on 06/23/2026 at 15:44, 4 months 12 days ago Aperçu de l'assemblée générale annuelle 2026 d'Heidelberg Pharma Conseil De Surveillance Assemblée Générale Annuelle Approbation Des Actionnaires Conjugués Anticorps-médicament Heidelberg Pharma
PRESS RELEASE published on 06/23/2026 at 15:39, 4 months 12 days ago Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2026 Heidelberg Pharma AG reports on the results of the Ordinary Annual General Meeting 2026, including approval of agenda items and election of new Supervisory Board member Annual General Meeting Supervisory Board Biotech Heidelberg Pharma AG Ordinary AGM
BRIEF published on 04/29/2026 at 07:10, 6 months 7 days ago Heidelberg Pharma AG Reports Progress in Q1 2026 Financial Results Clinical Trials Heidelberg Pharma HDP-101 Biotech Development
BRIEF published on 04/29/2026 at 07:10, 6 months 7 days ago Heidelberg Pharma AG annonce des progrès au premier trimestre 2026 Résultats Financiers Essais Cliniques Heidelberg Pharma HDP-101 Développement Biotechnologique
PRESS RELEASE published on 04/29/2026 at 07:05, 6 months 7 days ago Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2026 Heidelberg Pharma AG reports significant progress in the first quarter of 2026 financially and in clinical development, completion of Phase I clinical trial, milestone payments triggered, and extended cash reach Clinical Development Phase I Trial Heidelberg Pharma AG Milestone Payments Financial Progress
Published on 11/06/2026 at 13:00, 1 hour 36 minutes ago Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 2 hours 6 minutes ago Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 2 hours 6 minutes ago Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/06/2026 at 05:15, 9 hours 21 minutes ago Valeo and QNX Unveil A New Smart Camera Platform at CIIE, Secures Multiple Design Wins
Published on 11/06/2026 at 14:25, 11 minutes ago EQS-Adhoc: VANEA AG Specifies Outlook for Financial Year 2026 Based on German GAAP Separate Financial Statements
Published on 11/06/2026 at 14:23, 13 minutes ago Original-Research: Agilyx ASA (von Montega AG): Kaufen
Published on 11/06/2026 at 12:02, 2 hours 34 minutes ago First close-up asteroid image as ESA spacecraft built by OHB approaches historic rendezvous with the Didymos system
Published on 11/06/2026 at 09:07, 5 hours 29 minutes ago Mise à disposition de la note d'information de M14 dans le cadre de l'OPR visant les actions BOURRELIER GROUP
Published on 11/06/2026 at 09:04, 5 hours 31 minutes ago Mise à disposition de la note d'information en réponse établie par BOURRELIER GROUP initiée par M14
Published on 11/05/2026 at 18:21, 20 hours 15 minutes ago Capital et droits de vote au 31 octobre 2026